Aqua Pharmaceuticals, LLC

Size: px
Start display at page:

Download "Aqua Pharmaceuticals, LLC"

Transcription

1 Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1

2 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing prescription medical dermatology products Founded in 2004 Focus on under or non-promoted, branded dermatology drugs in US Market Commercial infrastructure with track record of success Stable and growing base business with high margins and strong cash flows Sales coverage in all major, high-value targets RoundTable made a controlling investment in June 2010 AQUA PHARMACEUTICALS, LLC 2

3 Strength in Management Jay Gooding, Co-Founder, Chief Executive Officer 26 years in Dermatology Stiefel Laboratories Sales, Training & Management Healthpoint Manager of Marketing & Product Development Bioglan Vice President of Marketing & Managed Care, Officer Craig Ballaron, Co-Founder, President, Treasurer and Secretary 26 years in Senior Management Ultra Precision President Bioglan - Senior Vice President, Sales & Finance / CFO David H. Crean, Vice President, Corporate Development 18 Years in Specialty Pharmaceuticals Allergan, Inc. Business Development for Dermatology, Neurology and Ophthalmology Allergan, Inc. Project and Portfolio Management, Research & Development Ted W. White, Vice-President, Sales +19 Years in Sales & Marketing Leadership Novartis Managing Director Primary Care, US Group Practice, Cardiovascular Skip Williams, Vice-President, Product Development 19 Years in Specialty Pharmaceuticals Watson Pharmaceuticals Business Development Nephrology, Dermatology, Biologics Accenture, System Software Associates, and Lexis-Nexis Kimberley Forbes-McKean, Vice-President, Research & Development +20 Years in Specialty Pharmaceuticals Dermik / Sanofi-Aventis- Global Development Cutanea Life Sciences and Isolagen, Inc.- CSO/ CTO, Development AQUA PHARMACEUTICALS, LLC 3

4 RoundTable Healthcare Partners RoundTable provides the experience, know how and capital to consummate a transaction Invested over $250 million in capital over the past year $1.9 billion in private equity buyout funds Fund I - $400 million private equity buyout fund raised in March 2002 Fund II - $500 million private equity buyout fund raised in March 2005 Capital Fund - $200 million subordinated debt investment fund raised in July 2006 Fund III - $600 million private equity buyout fund raised in July 2010 Capital Fund II - $200 million subordinated debt investment fund raised in July 2010 AQUA PHARMACEUTICALS, LLC 4

5 Dermatology Sector Attractive Macro Characteristics Dermatology represents one of the largest global markets for healthcare $14B+ market (2009) with 5% CAGR Highly diverse sector with overlapping segments (therapeutic, aesthetic, skin care) Market served by multiple, global, US and EU players of varying sizes, with some recent consolidation Big pharma- Sanofi, J&J, GSK, Roche, Bayer Large specialty- Nycomed, Galderma, Valeant, Allergan, Medicis Independents- Graceway, Obagi, SkinMedica, Triax, many others Fragmented nature of market comprised of numerous dispersed specialty pharmaceuticals presenting attractive consolidation opportunity Significant potential to exploit synergies acrss products, distribution, sales and marketing infrastructures Historically not a focus area for large pharma due to sub threshold blockbuster indications (i.e., low hanging fruit) Growth Drivers Source: 2011 BMO Capital Markets.Supported by Macro and Clinical Growth Drivers Widespread need with 1 out of every 3 people suffering from a dermatologic condition Increasing demand from aging populations treating accumulated dermatological conditions and co-morbidities Overlapping drug development opportunities across other therapeutic categories Major physician preference driven by life cycle management, product bundling, repeat aesthetic procedures Aesthetics resilience to macro economic trends: out of pocket payments, not subject to Medicare/ Healthcare reform AQUA PHARMACEUTICALS 5

6 $131 $115 $113 $99 $94 $84 $78 $74 $59 $58 $47 $47 $44 $42 $185 $165 $156 $223 $296 $280 $259 Revenue $USD MM $345 $340 $338 $410 $452 $448 $632 $872 $950 Fragmented Market in U.S. $1,000 US Dermatology Top 30 Players $900 $800 $700 $600 $500 $400 $300 $200 $100 $ IMS Health, Dermatology All Topical, Tetracycline Antibiotics, Isotretinoins AQUA PHARMACEUTICALS 6

7 Dermatology Segments Aqua has leading branded prescription drugs in four therapeutic categories including acne, steroid-responsive dermatoses, seborrheic dermatitis and actinic keratosis Acne market represents largest segment of overall dermatology market Sales of prescription and over-the-counter acne medications generate approximately $5 billion annually 15-20% of all consultations in dermatology related to acne Topical corticosteroid market is estimated at $500+ million Indications include atopic dermatitis, contact dermatitis and psoriasis Seborrheic dermatitis market Affects 1-3% of the immunocompetent adults 1.3MM uses in 2010 (OTC, Rx) AK market (actinic keratoses) pre-cancer skin condition: estimated 10 million people affected in the U.S. Estimated that 10% of AK advances to a cancerous state Favorable market dynamics with aging population AQUA PHARMACEUTICALS, LLC 7

8 Marketed Products Product Active Addressable Market Monodox Doxycycline, Oral Acne Cordran Flurandrenolide, topical Steroid-responsive Dermatoses Xolegel Ketoconazole, topical Seborrheic dermatitis Fluoroplex 5-Fluorouracil, topical Actinic Keratoses AQUA PHARMACEUTICALS, LLC 8

9 Corporate Growth Strategy Value creation is fueled through three-pronged approach Maximize Current Products Growth and Profit Acquire Companies and new products to expand product mix and core competencies Organic Growth Facilitate long term growth through R&D Pipeline and Product Development Product Development Corporate & Business Development AQUA PHARMACEUTICALS, LLC 9

10 Growing organizational capabilities Positioned for Future Growth Key Success Factors: Strategy, People and Execution

11 What s in our Sweet Spot? Aqua is looking for assets to add to its existing portfolio Dermatology assets for North America (US & Canada) Therapeutic, Aesthetic, Physician Dispensed, OTC No DESI products drug (505(b)(1), 505(b)(2) or device (PMA, 510K) Avoid capital equipment or box plug-in technology Brands, not generics Marketed assets with revenue and development stage assets for longer term growth Open to Corporate M&A to add greater capabilities Assets with patents or market/ regulatory exclusivity AQUA PHARMACEUTICALS, LLC 11

12 For corporate and business development opportunities, please contact: David H. Crean VP, Corporate Development Aqua Pharmaceuticals, LLC 158 West Gay Street Suite 310 West Chester, PA AQUA PHARMACEUTICALS, LLC 12

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

Lupin Limited Annual Results FY12. Investor Presentation May being

Lupin Limited Annual Results FY12. Investor Presentation May being Lupin Limited Annual Results FY12 Investor Presentation May 2012 Vision: To be an innovation led transnational company Journey over the last decade 5th largest generics player in US Gross Revenues INR

More information

Cross-Border R&D in China Understanding the Regulatory Challenges

Cross-Border R&D in China Understanding the Regulatory Challenges 1 2 Cross-Border R&D in China Understanding the Regulatory Challenges 1 Panelists Moderator: Paul A. Stewart, Silicon Valley Office Managing Partner, Foley & Lardner LLP Speakers: David Rosen, Partner,

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan NEWS PROVIDED BY New Rhein Healthcare Investors LLC Nov 22, 2016, 04:57 ET CHICAGO, Nov. 22, 2016 /PRNewswire/ --

More information

ALANCO TECHNOLOGIES INC

ALANCO TECHNOLOGIES INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

CHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come

CHINA MED DEVICE.   China Medtech Will Continue Its Double Digit Growth in Years to Come China Medtech Will Continue Its Double Digit Growth in Years to Come The high level characteristics of medtech in China is focused here. Each of the 6 specific sectors according to SWS recommendation will

More information

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China

Driving profitable growth in Greater China. Andy Ho Chief Market Leader Greater China Driving profitable growth in Greater China Andy Ho Chief Market Leader Greater China Key takeaways China HealthTech market is the 2 nd largest globally and exhibits continued robust growth with significant

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

Innovation and the Changing Practice of Medicine

Innovation and the Changing Practice of Medicine Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis

More information

State of Licensing 2011 Update

State of Licensing 2011 Update State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-

More information

Speed Innovation Happiness. Corporate Overview

Speed Innovation Happiness. Corporate Overview Corporate Overview Contents Bilcare Overview Businesses Business Strategy Financial Overview 2 Bilcare Overview 3 Bilcare Overview Our Objective Vision Delivering Innovation Transforming Lives Values Speed

More information

Recent Trend of Generic Medicines Market In Japan

Recent Trend of Generic Medicines Market In Japan Recent Trend of Generic Medicines Market In Japan Joint 22 nd EGA and 19 th IGBA Annual Conference Dubrovnik, Croatia 9 June, 2016 Itsuro Yoshida President of Japan Generic Medicines Association Copyright

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

An Experienced Approach to Private Equity

An Experienced Approach to Private Equity An Experienced Approach to Private Equity Monument MicroCap Partners, LLC (MMP) is an independent private investment firm comprised of highly experienced and accomplished private equity and operational

More information

LUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017

LUPIN LIMITED Q3FY17 Investor Presentation February 09, 2017 LUPIN LIMITED Investor Presentation February 09, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based

More information

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance Reynolds American Enters Smokeless Tobacco Category Via Acquisition of Conwood $3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category Deal at a Glance 2005 Financial Summary

More information

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE JOHN JACK R. TUPMAN, JR CURRICULUM VITAE September 2018 John R. Tupman, Jr. is a consultant focused on business development and licensing in the life sciences industry. He is currently working as a consultant

More information

Digital Medical Device Innovation: A Prescription for Business and IT Success

Digital Medical Device Innovation: A Prescription for Business and IT Success 10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

President and Chief Executive Officer and Director

President and Chief Executive Officer and Director Jeffrey P. Freimark 07/2008 to Present Miami Jewish Health Systems, Inc. A not-for-profit organization that is the largest and most innovative provider of health care for seniors in the Southeast. Miami

More information

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research

Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research Life Sciences New Jersey 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research 2 New Jersey Over the course of the past 130 years, the pharmaceutical/life sciences

More information

The Shape of Things to Come: Massachusetts June 18, 2010 Newton Marriott Hotel

The Shape of Things to Come: Massachusetts June 18, 2010 Newton Marriott Hotel The Shape of Things to Come: Massachusetts 2020 June 18, 2010 Newton Marriott Hotel Mark Nemec, Ph.D Managing Director, Technology Industry Client Group Forrester Research Some Thoughts on The Reset Economy

More information

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn

More information

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back.

PHARMA S NEW PHASE. Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom. They re back. Renew-New PHARMA S NEW PHASE Technological integrators play as crucial a role as banks in Big Pharma s latest M&A boom They re back. Mergers & acquisitions, that is and in a big way. Wall Street and City

More information

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking

More information

Generics Series: Authorized Generics Analysis Stemming the Generics Tide

Generics Series: Authorized Generics Analysis Stemming the Generics Tide Generics Series: Authorized Generics Analysis Stemming the Generics Tide Report summary An overview of the authorized generics landscape, including drivers and resistors for both branded and generics players

More information

Investing in Regional Sustainability Norris Lozano, PDC

Investing in Regional Sustainability Norris Lozano, PDC Investing in Regional Sustainability Norris Lozano, PDC Regional Leaders Seminar Series Institute of Metropolitan Studies Portland, OR May 10, 2004 1 The Portland Development Commission Housing Infrastructure

More information

An innovative medical dermatology product company utilising a novel drug active and proven drug delivery technology

An innovative medical dermatology product company utilising a novel drug active and proven drug delivery technology ASX / MEDIA RELEASE 21 March 2016 ACQUISITION OF BOTANIX PHARMACEUTICALS INC An innovative medical dermatology product company utilising a novel drug active and proven drug delivery technology HIGHLIGHTS

More information

HFMA January CFO Forum

HFMA January CFO Forum HFMA January CFO Forum January 26, 2018 St. Mark s Hospital Education Auditorium 1200 E. 3900 S. Salt Lake City, Utah 7.0 CPE hours 7:30 8:00 a.m. Continental Breakfast 8:00 8:15 a.m. Opening and Chapter

More information

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences

More information

Koen Dejonckheere. Professional experience. Board Memberships. Education

Koen Dejonckheere. Professional experience. Board Memberships. Education Koen Dejonckheere Professional experience KBC SECURITIES GROUP 2002-2008 Managing Director, responsible for Corporate Finance Previously, Koen Dejonckheere was active in Corporate Finance and Private Equity

More information

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported

More information

Revenue of $100 million to $1 billion and EBITDA in excess of $20 million

Revenue of $100 million to $1 billion and EBITDA in excess of $20 million NEWSTONE CAPITAL PARTNERS, LLC invests in mezzanine securities of larger middle-market companies involved in leveraged buyouts, recapitalizations, and later-stage growth financings. For the last 20 years,

More information

Venture Capital Search Highlights

Venture Capital Search Highlights Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more

More information

Bringing More to the Table

Bringing More to the Table Bringing More to the Table TM During this presentation and the Q&A session, we may be making forward-looking statements that reflect certain risks and uncertainties associated with Shuffle Master s business.

More information

UBS Global Healthcare Services Conference February 14, 2006

UBS Global Healthcare Services Conference February 14, 2006 UBS Global Healthcare Services Conference February 14, 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not

More information

Comprehensive Research Services

Comprehensive Research Services Comprehensive Research Services Scripps Health: At the Forefront of Clinical Research Scripps Health is a recognized leader in clinical research and has long been at the forefront of numerous medical breakthroughs.

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third

More information

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User

More information

HY2015. Disciplined performance management. Redefining the future for people and places 1. Attractive growth fundamentals & opportunities

HY2015. Disciplined performance management. Redefining the future for people and places 1. Attractive growth fundamentals & opportunities HY2015 Attractive growth fundamentals & opportunities Disciplined performance management Redefining the future for people and places 1 Overview Resilient underlying performance HY2015 Headline EPS 31.3p

More information

Investor Presentation. June 2006

Investor Presentation. June 2006 Investor Presentation June 2006 Forward-Looking Statements This presentation contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, the impact of

More information

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management

M&A Update 1H Proven. Focused. Trusted. Accounts Receivable Management Healthcare IT Revenue Cycle Management M&A Update 1H 2017 Accounts Receivable Management Healthcare IT Revenue Cycle Management Proven. Focused. Trusted. 301-576-4000 www.greenberg-advisors.com Proven. Focused. Trusted Revenue Cycle Management

More information

INVESTOR PRESENTATION!

INVESTOR PRESENTATION! INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING

More information

Presentation. March 2007

Presentation. March 2007 Presentation March 2007 1 Corporate Overview 2 Corporate Overview Leading provider of research-driven packaging solutions solely-focused on pharmaceutical industry Founded in 1994 and based in Pune, India

More information

ASX: UCW FULL YEAR RESULTS FOR THE YEAR ENDED 30 JUNE 2017

ASX: UCW FULL YEAR RESULTS FOR THE YEAR ENDED 30 JUNE 2017 ASX: UCW FULL YEAR RESULTS FOR THE YEAR ENDED 30 JUNE 2017 ABOUT UCW 1. Fee-for-service education provider with international student market focus 2. Vision to be a multi-sector provider - Vocational,

More information

Agenda. Genesys Capital Partners. The Opportunity. Our Approach

Agenda. Genesys Capital Partners. The Opportunity. Our Approach MEDT Dinner Presentation September 28, 2005 Agenda Genesys Capital Partners The Opportunity Our Approach Genesys Capital Partners Genesys Capital Partners Successful Track Record Management experience

More information

KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017

KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017 KKR & Co. L.P. Goldman Sachs U.S. Financial Services Conference: December 6, 2017 KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR Alternative AUM +12% CAGR ($ in trillions) ($ in billions)

More information

2015 Real Estate Industry Update A landscape for change: Transforming for the future

2015 Real Estate Industry Update A landscape for change: Transforming for the future 2015 Real Estate Industry Update A landscape for change: Transforming for the future December 11, 2015 Welcome Welcome to Deloitte s 2015 real estate industry update The real estate industry has been on

More information

Energy Recapitalization and Restructuring Fund, L.P. IPAA Presentation. January 2012

Energy Recapitalization and Restructuring Fund, L.P. IPAA Presentation. January 2012 Energy Recapitalization and Restructuring Fund, L.P. IPAA Presentation January 2012 Disclaimer 1 All figures are preliminary estimates and are subject to revision without notice. This confidential report

More information

The University of Texas School of Law 30 th Annual Health Law Conference

The University of Texas School of Law 30 th Annual Health Law Conference The University of Texas School of Law 30 th Annual Health Law Conference April 4-6, 2018, Royal Sonesta Hotel Houston, Texas Private Equity Transactions with Healthcare Providers Lisa Atlas Genecov Head

More information

Forum Science & Business FCRi - EY Foundation

Forum Science & Business FCRi - EY Foundation Forum Science & Business FCRi - EY Foundation How European Policy could help the Entrepreneurial and Venture Capital Ecosystems 16 th April 2015 Anne Glover Chief Executive, Amadeus Capital & EVCA Chairman

More information

The partner of choice for self-care products

The partner of choice for self-care products The partner of choice for self-care products Venture Life Group plc Full Year Results Presentation 2017 22 March 2018 2017 highlights Revenues up 12% to 16.1m (2016: 14.3m) Gross profit increased 18% to

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners

How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? Guy Nohra Co-Founder and Managing Director of Alta Partners How attractive is the BioRegion of Catalonia for foreign investment? M ost

More information

10 YEARS OF GENERIC MEDICINES IN BRASIL. Growth Earnings Challenges

10 YEARS OF GENERIC MEDICINES IN BRASIL. Growth Earnings Challenges 10 YEARS OF GENERIC MEDICINES IN BRASIL. Growth Earnings Challenges PróGenéricos - Generic Medicines Industries Association Odnir Finotti - CEO Brasil Population profile x Income x medicines access restriction

More information

Revenue of $100 million to $1 billion and EBITDA in excess of $20 million

Revenue of $100 million to $1 billion and EBITDA in excess of $20 million NEWSTONE CAPITAL PARTNERS, LLC invests in mezzanine securities of larger middle-market companies involved in leveraged buyouts, recapitalizations, and later-stage growth financings. For the last 20 years,

More information

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1 Patenting Strategies The First Steps Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1 Contents 1. The pro-patent era 2. Main drivers 3. The value of patents 4. Patent management 5. The strategic

More information

Jim Labe. The Global Leader in Venture Finance

Jim Labe. The Global Leader in Venture Finance Jim Labe CHIEF EXECUTIVE OFFICER & CO-FOUNDER Jim Labe is the Chief Executive Officer and co-founder of TriplePoint Capital. Mr. Labe is widely recognized as the pioneer of the venture leasing and lending

More information

Plan to split MTG into two listed companies

Plan to split MTG into two listed companies Plan to split MTG into two listed companies Today s presenters Jørgen Madsen Lindemann MTG President & Chief Executive Officer Anders Jensen MTG Executive Vice President; CEO of Nordic Entertainment Our

More information

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017

2017 Venture Capital Update. Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 2017 Venture Capital Update Bobby Franklin President & CEO, National Venture Capital Association (NVCA) January 2017 Agenda U.S. VC trends through year-end 2016 VC trends in Texas & Dallas Policy priorities

More information

napier napier balance napier 2004 ANNUAL REPORT

napier napier balance napier 2004 ANNUAL REPORT napier napier balance napier 2004 ANNUAL REPORT luxury introducing ner contemporary denim moderate boomer junior retail lifestyle career shoes acc letterfrom the C.E.O. Dear Jones Apparel Shareholder:

More information

Healthcare Products & Services Industry Update Q2 2017

Healthcare Products & Services Industry Update Q2 2017 Healthcare Products & Services Industry Update Q2 2017 Q2 M&A TRANSACTION SUMMARY Q2 Deal Volume (1) Healthcare Products & Services M&A decreased slightly following increased transaction activity in Q1

More information

Gerresheimer CAPITAL MARKETS DAY 2010

Gerresheimer CAPITAL MARKETS DAY 2010 Gerresheimer CAPITAL MARKETS DAY 2010 Gerresheimer Today September 1, 2010 Uwe Röhrhoff, CEO Gerresheimer who we are and what we do Gerresheimer is an important partner of the pharmaceutical and healthcare

More information

Opportunity in Small & Mid Cap

Opportunity in Small & Mid Cap Opportunity in Small & Mid Cap - A Private Equity Investing approach Presentation by Hiren Ved Alchemy Capital Management October 20 Presentation ti Path Investment Life Cycle Private equity opportunities

More information

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations

NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and

More information

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017

KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform. December 2017 KKR and FS Investments Form Strategic BDC Partnership Creates the Leading $18BN Alternative Lending Platform December 2017 Strategic BDC Partnership Introduction On December 11, 2017, KKR and FS Investments

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018

PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018 PRESS RELEASE FOR IMMEDIATE RELEASE NEX SYMBOL: AXQ JULY 25, 2018 RE: ACQUISITION OF TERRANUEVA PHARMA CORPORATION FOR $10,930,000 - CHANGE OF NAME - CONSOLIDATION - ANNOUNCEMENT OF A CONCURRENT PRIVATE

More information

Observations from Pharma

Observations from Pharma Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 1Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

TENOR CAPITAL PARTNERS. ESOP Leveraged Buyout Specialist,

TENOR CAPITAL PARTNERS. ESOP Leveraged Buyout Specialist, TENOR CAPITAL PARTNERS ESOP Leveraged Buyout Specialist, Tenor Capital Partners, LLC (TCP) is the leading boutique investment bank in the southeast focused exclusively on advising, and acting as advocate

More information

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans - Acquisitions, Financing, Expansion Initiatives & Strategic Plans MIRAMAR, FL, January 22, 2019 - Generex Biotechnology Corporation (www.generex.com)

More information

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

UNITED INTERNET. Business Applications Strategic Partnership with Warburg Pincus. November 8, Investor Presentation November 8, 2016

UNITED INTERNET. Business Applications Strategic Partnership with Warburg Pincus. November 8, Investor Presentation November 8, 2016 UNITED INTERNET Business Applications Strategic Partnership with Warburg Pincus November 8, 2016 1 Investor Presentation November 8, 2016 1&1 INTERNET SE WITHIN UNITED INTERNET GROUP WP XII Venture Holdings

More information

NOTICE To the Trustee of

NOTICE To the Trustee of NOTICE To the Trustee of Garfunkelux Holdco 3 S.A. (the Issuer ) 365,000,000 7.50% Senior Secured Notes due 2022 ISIN: XS1263891910, Common Code: 126389191 (Regulation S) ISIN: XS1263892561, Common Code:

More information

THE SMALL BIG DREAM. By AVEEK DATTA. 36 \ Forbes India \ July 24, 2015 TO DATE, YESTERYEAR BOLLYWOOD

THE SMALL BIG DREAM. By AVEEK DATTA. 36 \ Forbes India \ July 24, 2015 TO DATE, YESTERYEAR BOLLYWOOD THE SMALL BIG DREAM It took a second generation of Agrawals to change the future of Ajanta Pharma which, from being mired in debt, has seen a 65-fold growth in market value By AVEEK DATTA T TO DATE, YESTERYEAR

More information

CANADIAN PRIVATE EQUITY BUYOUT REVIEW

CANADIAN PRIVATE EQUITY BUYOUT REVIEW CANADIAN PRIVATE EQUITY BUYOUT REVIEW First Half 2016 REUTERS Table of Contents Canada s PE Buyout Market in Q2 2016 3 $ Invested and # Companies Financed 5 Top Buyout Deals 9 Canada by Market Segment

More information

Rovio Entertainment Corporation Annual General Meeting April 9, 2019 CEO REVIEW Kati Levoranta

Rovio Entertainment Corporation Annual General Meeting April 9, 2019 CEO REVIEW Kati Levoranta Rovio Entertainment Corporation Annual General Meeting April 9, 2019 CEO REVIEW Kati Levoranta TRANSLATED FROM THE FINNISH ORIGINAL Translated from the Finnish original. Finnish version prevails. Contents

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID

More information

PANEL DISCUSSION & ROUNDTABLES

PANEL DISCUSSION & ROUNDTABLES LIFE SCIENCES & HEALTH CARE EVENT Road to commercialization - Challenges, Opportunities & Successes that lie ahead in the Life Sciences and Healthcare Sectors Life Sciences and Healthcare is one of the

More information

Packaging M&A Boom or Bust

Packaging M&A Boom or Bust Packaging M&A Boom or Bust Will Frame Managing Director Deloitte & Touche Corporate Finance LLC October 3, 2007 www.investmentbanking.deloitte.com Table of Contents Recent Market Turmoil Let s Peel Back

More information

23 March Plan to split MTG into two listed companies

23 March Plan to split MTG into two listed companies 23 March 2018 Plan to split MTG into two listed companies Today s presenters Jørgen Madsen Lindemann MTG President & Chief Executive Officer Anders Jensen MTG Executive Vice President; CEO of Nordic Entertainment

More information

January Bob DeSutter Managing Director Co-Head of Health Care

January Bob DeSutter Managing Director Co-Head of Health Care January 2007 Dear Friends and Clients, For much of our 112 year history, serving innovative health care companies has been an important part of our mission at Piper Jaffray. Our goal is to be lead advisor

More information

Life Sciences Outlook

Life Sciences Outlook Life Sciences Outlook Raleigh- 2013-2014 Mid-tier biotech and specialty pharmaceuticals drive demand Across North America, activity and demand within the life sciences industry seems to have shifted from

More information

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board

September 18, 2017 Special Called Meeting of the U. T. System Board of Regents - Meeting of the Board AGENDA SPECIAL CALLED TELEPHONE MEETING of THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS September 18, 2017 Austin, Texas Page CONVENE THE BOARD IN OPEN SESSION TO RECESS TO EXECUTIVE SESSION PURSUANT

More information

KOHLBERG CAPITAL CORPORATION. May 2007

KOHLBERG CAPITAL CORPORATION. May 2007 KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These

More information

SPOTLIGHT PRIVATE EQUITY ACTIVITY INTRO TO PE DEALS VALUATION METRICS SPOT ON TESTING, INSPECTION & CERTIFICATION

SPOTLIGHT PRIVATE EQUITY ACTIVITY INTRO TO PE DEALS VALUATION METRICS SPOT ON TESTING, INSPECTION & CERTIFICATION SPOT ON TESTING, INSPECTION & CERTIFICATION Arjen Kostelijk, Oaklins testing, inspection & certification (TIC) specialist, is pleased to share an update on M&A in the sector in this third edition of Spot

More information

Life Sciences & Healthcare Venture Summit. Funding Healthcare & IT Media October 27, 2009

Life Sciences & Healthcare Venture Summit. Funding Healthcare & IT Media October 27, 2009 Life Sciences & Healthcare Venture Summit Funding Healthcare & IT Media October 27, 2009 Emilio Ragosa Emilio Ragosa is a partner in Morgan Lewis's Business and Finance Practice. He focuses primarily on

More information

Raymond A. Snead, Jr., D. Sc., FHFMA, FACHE

Raymond A. Snead, Jr., D. Sc., FHFMA, FACHE Doctor of Healthcare Administration and currently practicing CFO whose thirty-five-year career includes serving as the President, Executive Vice President and Chief Financial Officer of for profit and

More information

Electronic Material Systems

Electronic Material Systems Electronic Material Systems Barry Russell Operating Vice President 1 Safe Harbor Statement Today s presentations may contain forward-looking statements within the meaning of the Private Securities Litigation

More information